in4thelonghaul

Is Medarex's Prostate Cancer Drug a Success? Too Early to Tell

You think maybe Dr. Kwon was cognizant of the unorthodox timing of his comments and thus the scrutiny which he and Mayo would be under? Now why would he take such a chance unless he had weighed the potential benefits against the serious consequences?

Think about it Derek...

Weren't you the same guy that lined up with Cramer against DNDN?

You don't exactly have a stellar track record do you?

I agree with others...you should really try and do a bit of proper DD before expressing such dismissive attitude.

Much Ado About Medarex

This is a tough one simply because of the odd and unorthodox nature regarding the manner this stunningly positive "news" came public and of course the small amount of patients involved - apparently 3 patients now, not just the first 2 mentioned originally.

Astute biotech watchers will remember that some very serious side-effects have been linked with use of ipilimumab in past trials.

Obviously, if Mayo is still attempting to enroll patients, questions can legitimately be raised as to motivation for the timing, wording and manner of the 'news' which found its way to the public...maybe nothing there, time will tell.

It will all be moot if serious side-effects have been avoided and further patients are revealed to have achieved similarly stunning results, results where cancer has apparently vanished. I find it unlikely that the story is anything less than has been portrayed, simply because Mayo's reputation is on the line here.

I think everyone's hope is for these first and apparently stunning results to be repeated in other patients in the treatment arm.

Biotech shareholders of companies with competing treatments have expressed some justified skepticism. MEDX shareholders can expect to achieve considerable sh/pr appreciation in the coming years if these results are as indicated and widespread, even more so if ipilimumab is successful with melanoma.

Considering the potential, it seems shares around $8.00 present a decent risk/reward. If the melanoma trial disappoints, MEDX shares could easily retest their recent lows and remain depressed for considerable time, especially if serious side effects are again linked with use if ipilimumab. OTOH, if all goes well, MEDX has a potential blockbuster on their hands and shares could easily skyrocket towards $30.00 in quick order.